Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor
- Paris Abrams, Christopher R. Emerson
- Medicine
- Pharmacotherapy
- 1 February 2009
Thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke often result in long‐term disability and/or mortality. The anticoagulants currently… Expand
Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
- Christopher R. Emerson, Nino Marzella
- Medicine
- Clinical therapeutics
- 1 August 2010
BACKGROUND
Dexlansoprazole, the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. It is indicated for healing all grades… Expand
Economic Impact of Implementing Pneumonia Treatment Guidelines for Intravenous to Oral Conversion
- Christopher R. Emerson, Marilena S. Antonopoulos, Nino Marzella, S. S. Grossman
- Medicine
- 1 November 2008
Background Inpatient treatment of pneumonia produces significant costs to the health care system. In an effort to improve quality of care, decrease length of stay, and decrease drug costs associated… Expand
Clostridium difficile—Associated Diarrhea, an Emerging Epidemic: Therapeutic Options
- Christopher R. Emerson
- Medicine
- 1 August 2007
Clostridum difficile—associated disease (CDAD) is the leading cause of infectious diarrhea and is associated with considerable morbidity and mortality. The incidence is estimated to range from 3.4 to… Expand
The Administration of rt-PA (Activase®) for the Treatment of Empyema in an Adult Patient
- Christopher R. Emerson, Christine M. Bercume, Marilena S. Antonopoulos, Nino Marzella
- Medicine
- 1 February 2009
The administration of various fibrinolytic agents for the treatment of empyema has been reported in past studies. Most of the current literature has shown favorable outcomes in terms of increased… Expand
Ramoplanin: A Promising Treatment Option for Clostridium difficile -Associated Diarrhea and Vancomycin-Resistant Enterococcus
- Christopher R. Emerson, Nino Marzella
- Medicine
- 2007
INTRODUCTION The emergence of resistant path ogens, along with a lack of novel anti microbial agents in the pharmaceutical pipeline, is becoming a growing problem in treating nosocomial infections.… Expand
- 1
- PDF